DexCom, Inc. $DXCM Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 51.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,080 shares of the medical device company’s stock after selling 9,440 shares during the period. Arcadia Investment Management Corp MI’s holdings in DexCom were worth $603,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CVA Family Office LLC grew its holdings in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the period. ORG Partners LLC grew its holdings in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares during the period. Spire Wealth Management grew its holdings in DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after acquiring an additional 305 shares during the period. Aventura Private Wealth LLC acquired a new stake in DexCom during the fourth quarter worth about $43,000. Finally, Rothschild Investment LLC grew its holdings in DexCom by 59.9% during the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock worth $44,000 after acquiring an additional 245 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on DXCM. Citigroup reaffirmed a “buy” rating and set a $84.00 target price (up from $79.00) on shares of DexCom in a report on Thursday. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Piper Sandler reissued an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Truist Financial reissued a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Finally, Wells Fargo & Company dropped their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.42.

Insider Activity

In other news, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,871 shares of company stock worth $2,306,638 over the last quarter. 0.28% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of DXCM opened at $73.74 on Monday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The stock’s 50 day moving average is $64.17 and its two-hundred day moving average is $66.53. The firm has a market cap of $28.45 billion, a P/E ratio of 31.51, a PEG ratio of 1.22 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 earnings per share. Analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.